抗リウマチ薬市場：薬剤クラス別、投与経路別、タイプ別、疾患タイプ別、流通チャネル別-2025～2030年の世界予測

抗リウマチ薬市場は、2023年に915億4,000万米ドルとなり、2024年には965億6,000万米ドル、CAGR 5.68%で成長し、2030年には1,347億7,000万米ドルに達すると予測されています。

抗リウマチ剤の世界市場は、進化する治療情勢を深く理解する必要がある、注目すべき変化の時代を迎えています。近年、利害関係者は治療方法のかつてない進歩を目の当たりにし、様々なセグメントで着実かつ有望な成長を牽引しています。本レポートでは、現在の産業指標を反映するだけでなく、将来の課題と機会も予測した詳細な分析を発表します。患者の需要の増加と革新的な研究開発が相まって、市場関係者は従来の治療戦略を再評価し、新たな治療アプローチを取り入れるようになりました。医療環境のダイナミックな性質は、協調と競合の精神を育み、患者の転帰の大幅な改善と製品パイプラインの強化につながっています。さらに、世界の施策と規制改革が進展し、製品承認の迅速化と市場の信頼性向上に向けた道筋が合理化されました。堅牢なデータ分析と先進的デジタルツールを活用した本調査は、意思決定者や産業の専門家にとって不可欠な包括的見解を示しています。本ブリーフィングは、リューマチ対策市場の複雑さを理解するための入門書であり、主要な産業動向と競争戦略を詳細に調査するための土台となります。

抗リウマチ薬市場の変革

近年、抗リューマチックス市場は、医療技術革新と患者ケアの最前線に位置づけられ、変貌を遂げています。この産業では先進的研究手法が急増し、標的治療や個別化治療の開発が可能になりました。こうした技術革新は、バイオテクノロジーの向上とリウマチ性疾患の病態生理学の深い理解によって推進されてきました。規制の枠組みにも大きな変化が見られ、いくつかの地域の当局が承認プロセスを迅速化した結果、画期的な治療法の市場参入が早まりました。共同事業や戦略的パートナーシップは研究開発を強化し、特定の炎症経路を対象とする新規薬剤の普及につながっています。さらに、デジタルヘルスとデータ分析の導入に顕著な焦点が当てられており、これにより診断と患者モニタリングが改善され、最終的に治療成績が向上しています。患者がより効果的で安全な代替医療を求める中、産業は最先端技術を従来の医療モデルに統合することで迅速に対応してきました。この適応的なアプローチは、提供する製品を多様化させただけでなく、市場競合を強化しました。開発の動向は、抗リウマチ薬市場において、技術と医薬品開発の融合が成功の重要な決定要因であり続けることを示しています。

リューマチ対策市場の詳細なセグメンテーション分析

詳細な市場セグメンテーション分析により、抗リューマチ薬市場の複雑さが明らかになり、患者ケアと商業的成功を促進する多次元的要因が浮き彫りになります。市場は薬剤クラス別に分類され、副腎皮質ステロイド薬、疾患修飾性抗リウマチ薬、非ステロイド性抗炎症薬、尿酸薬の詳細な調査が含まれます。疾患修飾性抗リウマチ薬のセグメントで特に注目すべきは、生物学的DMARDs、従来型DMARDs、標的合成DMARDsに細分化されていることです。生物学的DMARDsの各セグメントは、B細胞阻害剤、インターロイキン阻害剤、T細胞共刺激調節剤、腫瘍壊死因子（TNF）阻害剤に基づいてさらに検討され、特定の作用機序と治療上のニュアンスを明確にしています。さらに、この分析は投与経路にも及んでおり、注射剤、経口剤、局所剤の動態を把握することで、患者の嗜好と臨床効果を一致させる役割を果たしています。製品タイプによるセグメンテーションでは、市販薬と処方薬ベースの医薬品を区別することで、規制要件と市場アクセスの整合性を図っています。疾患タイプでは、強直性脊椎炎、滑液包炎、痛風、若年性特発性関節炎、骨関節炎、骨粗鬆症、リウマチ性多発筋痛、乾癬性関節炎、関節リウマチ、シェーグレン症候群、全身性エリテマトーデス、全身性強皮症/強皮症、腱炎などの疾患を検討することで、市場調査をさらに細分化します。セグメンテーションの最終層では、これらの治療の入手と商品化において重要な役割を果たす、病院薬局、オンライン薬局、小売薬局に焦点を当て、流通チャネルを検討します。この包括的なセグメンテーションにより、市場の詳細なパノラマが把握され、利害関係者に将来のビジネス機会がどこにあるのかについての戦略的洞察が提供されます。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • リウマチ性疾患の有病率の増加
    • 関節リウマチの早期スクリーニングと治療に関する意識の高まり
    • 精密治療と個別化医療への重点化
  • 抑制要因
    • 抗リウマチ薬に伴う副作用と安全性の問題
  • 機会
    • リウマチ性疾患の研究開発に対する政府の取り組みと支援
    • 費用対効果の高いバイオシミラーの重要な開発と販売
  • 課題
    • 複雑な医薬品開発と承認プロセス
• 市場セグメンテーション分析
  • 薬剤クラス：入手しやすさ、手頃な価格、効果的な疼痛管理のため、非ステロイド性抗炎症薬の採用が増加
  • 投与経路：バイオアベイラビリティの向上と副作用の最小化を目的とした経口薬製剤の進歩
  • タイプ：重度と慢性リウマチ性疾患の管理において処方薬が優先される
  • 疾患タイプ：関節リウマチにおける個別化医療の進歩により、治療結果を最適化し、副作用を最小限に抑える
  • 流通チャネル：抗リウマチ薬の流通のためのオンライン薬局の拡大
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 法律
  • 環境

第6章 抗リウマチ薬市場：薬剤クラス別

• イントロダクション
• コルチコステロイド
• 疾患修飾薬抗リウマチ薬
  • 生物学的DMARD
    • B細胞阻害剤
    • インターロイキン阻害剤
    • T細胞共刺激調節因子
    • 腫瘍壊死因子（TNF）阻害剤
  • 従来型DMARD
  • 標的合成DMARD
• 非ステロイド性抗炎症薬
• 尿酸薬

第7章 抗リウマチ薬市場：投与経路別

• イントロダクション
• 注射剤
• 経口
• 局所

第8章 抗リウマチ薬市場：タイプ別

• イントロダクション
• 市販薬
• 処方薬

第9章 抗リウマチ薬市場：疾患タイプ別

• イントロダクション
• 強直性脊椎炎
• 滑液包炎
• 痛風
• 若年性特発性関節炎
• 変形性関節症
• 骨粗鬆症
• 多発性筋痛症
• 乾癬性関節炎
• 関節リウマチ
• シェーグレン症候群
• 全身性エリテマトーデス
• 全身性強皮症
• 腱炎

第10章 抗リウマチ薬市場：流通チャネル別

• イントロダクション
• 病院薬局
• オンライン薬局
• 小売薬局

第11章 南北アメリカの抗リウマチ薬市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋の抗リウマチ薬市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカの抗リウマチ薬市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• AbbVie Inc.
• Alvotech
• Amgen Inc.
• ANI Pharmaceuticals, Inc.
• AstraZeneca PLC
• Bayer AG
• Biogen Inc.
• Bristol-Myers Squibb Company
• C. H. Boehringer Sohn AG & Co. KG
• DeepCure
• Eisai Co., Ltd.
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• Fresenius Kabi AG
• Galapagos NV
• Gilead Sciences, Inc.
• GlaxoSmithKline PLC
• ILTOO Pharma SAS
• Johnson & Johnson Services Inc.
• medac GmbH
• Merck & Co., Inc.
• Novartis AG
• Otter Pharmaceuticals, LLC by Assertio Holdings, Inc.
• Pfizer, Inc.
• Regeneron Pharmaceuticals, Inc.
• Sanofi SA
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd.
• UCB S.A.
• Vertex Pharmaceuticals Incorporated

LIST OF FIGURES

• FIGURE 1. ANTI-RHEUMATICS MARKET MULTI-CURRENCY
• FIGURE 2. ANTI-RHEUMATICS MARKET MULTI-LANGUAGE
• FIGURE 3. ANTI-RHEUMATICS MARKET RESEARCH PROCESS
• FIGURE 4. ANTI-RHEUMATICS MARKET SIZE, 2023 VS 2030
• FIGURE 5. GLOBAL ANTI-RHEUMATICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 6. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
• FIGURE 15. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 17. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 21. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 23. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 24. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 25. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 26. ANTI-RHEUMATICS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 27. ANTI-RHEUMATICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. ANTI-RHEUMATICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL ANTI-RHEUMATICS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. ANTI-RHEUMATICS MARKET DYNAMICS
• TABLE 7. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY B-CELL INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY T-CELL CO-STIMULATION MODULATORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TUMOR NECROSIS FACTOR (TNF) INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY CONVENTIONAL DMARDS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TARGETED SYNTHETIC DMARDS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY URIC ACID DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY PRESCRIPTION-BASED DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ANKYLOSING SPONDYLITIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY BURSITIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY GOUT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY JUVENILE IDIOPATHIC ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY OSTEOARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY OSTEOPOROSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY POLYMYALGIA RHEUMATICA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 36. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY PSORIATIC ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 37. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 38. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY SJOGREN'S SYNDROME, BY REGION, 2018-2030 (USD MILLION)
• TABLE 39. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 40. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY SYSTEMIC SCLEROSIS/SCLERODERMA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 41. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TENDINITIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 42. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 43. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 44. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 45. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 46. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 47. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
• TABLE 48. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
• TABLE 49. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 50. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 51. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 52. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 53. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 54. ARGENTINA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 55. ARGENTINA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
• TABLE 56. ARGENTINA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
• TABLE 57. ARGENTINA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 58. ARGENTINA ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 59. ARGENTINA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 60. ARGENTINA ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 61. BRAZIL ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 62. BRAZIL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
• TABLE 63. BRAZIL ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
• TABLE 64. BRAZIL ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 65. BRAZIL ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 66. BRAZIL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 67. BRAZIL ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 68. CANADA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 69. CANADA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
• TABLE 70. CANADA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
• TABLE 71. CANADA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 72. CANADA ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 73. CANADA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 74. CANADA ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 75. MEXICO ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 76. MEXICO ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
• TABLE 77. MEXICO ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
• TABLE 78. MEXICO ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 79. MEXICO ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 80. MEXICO ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 81. MEXICO ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 82. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 83. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
• TABLE 84. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
• TABLE 85. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 86. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 87. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 88. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 89. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 90. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 91. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
• TABLE 92. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
• TABLE 93. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 94. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 95. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 96. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 97. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 98. AUSTRALIA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 99. AUSTRALIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
• TABLE 100. AUSTRALIA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
• TABLE 101. AUSTRALIA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 102. AUSTRALIA ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 103. AUSTRALIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 104. AUSTRALIA ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 105. CHINA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 106. CHINA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
• TABLE 107. CHINA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
• TABLE 108. CHINA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 109. CHINA ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 110. CHINA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 111. CHINA ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 112. INDIA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 113. INDIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
• TABLE 114. INDIA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
• TABLE 115. INDIA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 116. INDIA ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 117. INDIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 118. INDIA ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 119. INDONESIA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 120. INDONESIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
• TABLE 121. INDONESIA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
• TABLE 122. INDONESIA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 123. INDONESIA ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 124. INDONESIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 125. INDONESIA ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 126. JAPAN ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 127. JAPAN ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
• TABLE 128. JAPAN ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
• TABLE 129. JAPAN ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 130. JAPAN ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 131. JAPAN ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 132. JAPAN ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 133. MALAYSIA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 134. MALAYSIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
• TABLE 135. MALAYSIA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
• TABLE 136. MALAYSIA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 137. MALAYSIA ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 138. MALAYSIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 139. MALAYSIA ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 140. PHILIPPINES ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 141. PHILIPPINES ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
• TABLE 142. PHILIPPINES ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
• TABLE 143. PHILIPPINES ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 144. PHILIPPINES ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 145. PHILIPPINES ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 146. PHILIPPINES ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 147. SINGAPORE ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 148. SINGAPORE ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
• TABLE 149. SINGAPORE ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
• TABLE 150. SINGAPORE ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 151. SINGAPORE ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 152. SINGAPORE ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 153. SINGAPORE ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 154. SOUTH KOREA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 155. SOUTH KOREA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
• TABLE 156. SOUTH KOREA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
• TABLE 157. SOUTH KOREA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 158. SOUTH KOREA ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 159. SOUTH KOREA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 160. SOUTH KOREA ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 161. TAIWAN ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 162. TAIWAN ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
• TABLE 163. TAIWAN ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
• TABLE 164. TAIWAN ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 165. TAIWAN ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 166. TAIWAN ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 167. TAIWAN ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 168. THAILAND ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 169. THAILAND ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
• TABLE 170. THAILAND ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
• TABLE 171. THAILAND ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 172. THAILAND ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 173. THAILAND ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 174. THAILAND ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 175. VIETNAM ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 176. VIETNAM ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
• TABLE 177. VIETNAM ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
• TABLE 178. VIETNAM ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 179. VIETNAM ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 180. VIETNAM ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 181. VIETNAM ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 182. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 183. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
• TABLE 184. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
• TABLE 185. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 186. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 187. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 188. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 189. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 190. DENMARK ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 191. DENMARK ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
• TABLE 192. DENMARK ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
• TABLE 193. DENMARK ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 194. DENMARK ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 195. DENMARK ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 196. DENMARK ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 197. EGYPT ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 198. EGYPT ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
• TABLE 199. EGYPT ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
• TABLE 200. EGYPT ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 201. EGYPT ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 202. EGYPT ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 203. EGYPT ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 204. FINLAND ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 205. FINLAND ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
• TABLE 206. FINLAND ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
• TABLE 207. FINLAND ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 208. FINLAND ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 209. FINLAND ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 210. FINLAND ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 211. FRANCE ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 212. FRANCE ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
• TABLE 213. FRANCE ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
• TABLE 214. FRANCE ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 215. FRANCE ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 216. FRANCE ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 217. FRANCE ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 218. GERMANY ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 219. GERMANY ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
• TABLE 220. GERMANY ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
• TABLE 221. GERMANY ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 222. GERMANY ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 223. GERMANY ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 224. GERMANY ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 225. ISRAEL ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 226. ISRAEL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
• TABLE 227. ISRAEL ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
• TABLE 228. ISRAEL ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 229. ISRAEL ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 230. ISRAEL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 231. ISRAEL ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 232. ITALY ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 233. ITALY ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
• TABLE 234. ITALY ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
• TABLE 235. ITALY ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 236. ITALY ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 237. ITALY ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 238. ITALY ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 239. NETHERLANDS ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 240. NETHERLANDS ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
• TABLE 241. NETHERLANDS ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
• TABLE 242. NETHERLANDS ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 243. NETHERLANDS ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 244. NETHERLANDS ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 245. NETHERLANDS ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 246. NIGERIA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 247. NIGERIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
• TABLE 248. NIGERIA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
• TABLE 249. NIGERIA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 250. NIGERIA ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 251. NIGERIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 252. NIGERIA ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 253. NORWAY ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 254. NORWAY ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
• TABLE 255. NORWAY ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
• TABLE 256. NORWAY ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 257. NORWAY ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 258. NORWAY ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 259. NORWAY ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 260. POLAND ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 261. POLAND ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
• TABLE 262. POLAND ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
• TABLE 263. POLAND ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 264. POLAND ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 265. POLAND ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 266. POLAND ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 267. QATAR ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 268. QATAR ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
• TABLE 269. QATAR ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
• TABLE 270. QATAR ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 271. QATAR ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 272. QATAR ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 273. QATAR ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 274. RUSSIA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 275. RUSSIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
• TABLE 276. RUSSIA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
• TABLE 277. RUSSIA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 278. RUSSIA ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 279. RUSSIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 280. RUSSIA ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 281. SAUDI ARABIA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 282. SAUDI ARABIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
• TABLE 283. SAUDI ARABIA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
• TABLE 284. SAUDI ARABIA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 285. SAUDI ARABIA ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 286. SAUDI ARABIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 287. SAUDI ARABIA ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 288. SOUTH AFRICA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 289. SOUTH AFRICA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
• TABLE 290. SOUTH AFRICA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
• TABLE 291. SOUTH AFRICA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 292. SOUTH AFRICA ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 293. SOUTH AFRICA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 294. SOUTH AFRICA ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 295. SPAIN ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 296. SPAIN ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
• TABLE 297. SPAIN ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
• TABLE 298. SPAIN ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 299. SPAIN ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 300. SPAIN ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 301. SPAIN ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 302. SWEDEN ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 303. SWEDEN ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
• TABLE 304. SWEDEN ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
• TABLE 305. SWEDEN ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 306. SWEDEN ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 307. SWEDEN ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 308. SWEDEN ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 309. SWITZERLAND ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 310. SWITZERLAND ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
• TABLE 311. SWITZERLAND ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
• TABLE 312. SWITZERLAND ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 313. SWITZERLAND ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 314. SWITZERLAND ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 315. SWITZERLAND ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 316. TURKEY ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 317. TURKEY ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
• TABLE 318. TURKEY ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
• TABLE 319. TURKEY ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 320. TURKEY ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 321. TURKEY ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 322. TURKEY ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 323. UNITED ARAB EMIRATES ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 324. UNITED ARAB EMIRATES ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
• TABLE 325. UNITED ARAB EMIRATES ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
• TABLE 326. UNITED ARAB EMIRATES ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 327. UNITED ARAB EMIRATES ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 328. UNITED ARAB EMIRATES ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 329. UNITED ARAB EMIRATES ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 330. UNITED KINGDOM ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 331. UNITED KINGDOM ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
• TABLE 332. UNITED KINGDOM ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
• TABLE 333. UNITED KINGDOM ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 334. UNITED KINGDOM ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 335. UNITED KINGDOM ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 336. UNITED KINGDOM ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 337. ANTI-RHEUMATICS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 338. ANTI-RHEUMATICS MARKET, FPNV POSITIONING MATRIX, 2023

The Anti-Rheumatics Market was valued at USD 91.54 billion in 2023 and is projected to grow to USD 96.56 billion in 2024, with a CAGR of 5.68%, reaching USD 134.77 billion by 2030.

The global market for anti-rheumatics is undergoing an era of notable change that calls for a deep understanding of the evolving therapeutic landscape. In recent years, stakeholders have observed unprecedented advancements in treatment modalities, driving a steady and promising growth in various segments. This report introduces a detailed analysis that not only reflects current industry metrics but also anticipates future challenges and opportunities. Over time, increasing patient demand paired with innovative research and development has encouraged market players to reevaluate conventional treatment strategies and embrace novel therapeutic approaches. The dynamic nature of the healthcare environment has fostered a spirit of collaboration and competition, leading to significant improvements in patient outcomes and enhanced product pipelines. Furthermore, evolving global policies and regulatory reforms have streamlined pathways for faster product approvals and heightened market confidence. Leveraging robust data analytics and advanced digital tools, the study presents a comprehensive view that is essential for decision-makers and industry experts. This briefing serves as a primer to understand the complexities of the anti-rheumatics market, setting the stage for a detailed exploration of key industry trends and competitive strategies.

Transformative Shifts in the Anti-Rheumatics Market Landscape

Recent years have witnessed transformative shifts that have reshaped the anti-rheumatics market, positioning it at the frontier of medical innovation and patient care. The industry has experienced a surge in advanced research methodologies, enabling the development of targeted treatments and personalized therapies. These innovations have been driven by improvements in biotechnology and a deeper understanding of the pathophysiology of rheumatic diseases. A significant shift has been observed in the regulatory framework where authorities across several regions have expedited the approval processes, resulting in quicker market access for groundbreaking therapies. Collaborative ventures and strategic partnerships have bolstered research and development, leading to a proliferation of novel agents that target specific inflammatory pathways. Additionally, there has been a pronounced focus on embracing digital health and data analytics, which has improved diagnostics and patient monitoring, ultimately enhancing therapeutic outcomes. As patients demand more effective and safer alternatives, the industry has responded rapidly by integrating state-of-the-art technologies with traditional healthcare models. This adaptive approach has not only diversified the product offerings but has also strengthened market competitiveness. Emerging trends indicate that the convergence of technology with pharmaceutical development will continue to be a critical determinant of success in the anti-rheumatics market.

In-Depth Segmentation Insights Across the Anti-Rheumatics Market

A detailed segmentation analysis reveals the intricacies of the anti-rheumatics market and underscores the multi-dimensional factors driving patient care and commercial success. The market is categorized based on drug class, which includes an in-depth study of Corticosteroids, Disease Modifying Anti-rheumatics Drugs, Nonsteroidal Anti-inflammatory Drugs, and Uric Acid Drugs. Particularly noteworthy within the Disease Modifying Anti-rheumatics Drugs segment is the subdivision into Biologic DMARDs, Conventional DMARDs, and Targeted Synthetic DMARDs. Each segment within the Biologic DMARDs is further examined based on B-cell Inhibitors, Interleukin Inhibitors, T-cell Co-stimulation Modulators, and Tumor Necrosis Factor (TNF) Inhibitors, offering clarity on specific mechanisms of action and therapeutic nuances. Additionally, the analysis extends to the route of administration, capturing the dynamics of Injectable, Oral, and Topical formulations, which serve to match patient preference with clinical effectiveness. Segmentation based on product type distinguishes Over-the-Counter from Prescription-Based Drugs, thereby aligning regulatory requirements with market access. Disease type further refines the market study by considering conditions including Ankylosing Spondylitis, Bursitis, Gout, Juvenile Idiopathic Arthritis, Osteoarthritis, Osteoporosis, Polymyalgia Rheumatica, Psoriatic Arthritis, Rheumatoid Arthritis, Sjogren's Syndrome, Systemic Lupus Erythematosus, Systemic Sclerosis/Scleroderma, and Tendinitis. The final layer of segmentation examines distribution channels, highlighting Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies, which play a critical role in the accessibility and commercialization of these therapies. This comprehensive segmentation captures the detailed panorama of the market, offering stakeholders strategic insights into where future opportunities lie.

Based on Drug Class, market is studied across Corticosteroids, Disease Modifying Anti-rheumatics Drugs, Nonsteroidal Anti-inflammatory Drugs, and Uric Acid Drugs. The Disease Modifying Anti-rheumatics Drugs is further studied across Biologic DMARDs, Conventional DMARDs, and Targeted Synthetic DMARDs. The Biologic DMARDs is further studied across B-cell Inhibitors, Interleukin Inhibitors, T-cell Co-stimulation Modulators, and Tumor Necrosis Factor (TNF) Inhibitors.

Based on Route Of Administration, market is studied across Injectable, Oral, and Topical.

Based on Type, market is studied across Over-the-Counter Drugs and Prescription-Based Drugs.

Based on Disease Type, market is studied across Ankylosing Spondylitis, Bursitis, Gout, Juvenile Idiopathic Arthritis, Osteoarthritis, Osteoporosis, Polymyalgia Rheumatica, Psoriatic Arthritis, Rheumatoid Arthritis, Sjogren's Syndrome, Systemic Lupus Erythematosus, Systemic Sclerosis/Scleroderma, and Tendinitis.

Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.

Key Regional Insights: Navigating Global Opportunities in Anti-Rheumatics

Regional dynamics play a pivotal role in shaping the future trajectory of the anti-rheumatics market, and a nuanced understanding of geographical trends is essential. In the Americas, robust healthcare infrastructure and proactive policy measures have propelled the adoption of advanced therapies. The region presents lucrative opportunities anchored by high awareness, substantial investment in research, and progressive regulatory frameworks. Europe, Middle East & Africa is witnessing significant transformations with a focus on integrating traditional treatment models with novel therapeutic approaches. Stakeholders in this diverse region are increasingly examining the balance between cost-effectiveness and scientific innovation, paving the way for breakthrough approvals and enhanced patient outcomes. The Asia-Pacific region stands out due to its dynamic economic growth and rising middle-class populations that are driving an increased demand for quality healthcare services. Rapid urbanization, coupled with government initiatives to enhance healthcare access, has created a fertile ground for market expansion. By evaluating these regional insights, industry leaders can better strategize product positioning and market penetration, taking into account local regulatory landscapes, cultural nuances, and economic factors that influence patient care and adoption rates.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Comprehensive Analysis of Leading Companies in the Anti-Rheumatics Sector

The competitive landscape within the anti-rheumatics market is characterized by the presence of several key companies that are spearheading innovation and market expansion. Prominent entities such as AbbVie Inc., Alvotech, Amgen Inc., ANI Pharmaceuticals, Inc., and AstraZeneca PLC are at the forefront of developing and commercializing advanced therapies. Esteemed organizations like Bayer AG, Biogen Inc., Bristol-Myers Squibb Company, and C. H. Boehringer Sohn AG & Co. KG have consistently demonstrated excellence in clinical research and development. Emerging innovators including DeepCure and Eisai Co., Ltd. are also making significant inroads with specialized treatment offerings. Industry giants like Eli Lilly and Company, F. Hoffmann-La Roche Ltd., and Fresenius Kabi AG continue to leverage extensive research networks to drive product innovation. In addition, organizations such as Galapagos NV, Gilead Sciences, Inc., GlaxoSmithKline PLC, and ILTOO Pharma SAS provide crucial insights into market strategies and emerging trends. Well-established names including Johnson & Johnson Services Inc., medac GmbH, Merck & Co., Inc., and Novartis AG underscore the market's competitive intensity. Not to be overlooked are companies like Otter Pharmaceuticals, LLC by Assertio Holdings, Inc., Pfizer, Inc., Regeneron Pharmaceuticals, Inc., Sanofi SA, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., UCB S.A., and Vertex Pharmaceuticals Incorporated, whose collaborative efforts continue to redefine therapeutic standards in the field. Their strategic initiatives not only drive competitive advancements but also significantly impact the overall market dynamics.

The report delves into recent significant developments in the Anti-Rheumatics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Alvotech, Amgen Inc., ANI Pharmaceuticals, Inc., AstraZeneca PLC, Bayer AG, Biogen Inc., Bristol-Myers Squibb Company, C. H. Boehringer Sohn AG & Co. KG, DeepCure, Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Fresenius Kabi AG, Galapagos NV, Gilead Sciences, Inc., GlaxoSmithKline PLC, ILTOO Pharma SAS, Johnson & Johnson Services Inc., medac GmbH, Merck & Co., Inc., Novartis AG, Otter Pharmaceuticals, LLC by Assertio Holdings, Inc., Pfizer, Inc., Regeneron Pharmaceuticals, Inc., Sanofi SA, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., UCB S.A., and Vertex Pharmaceuticals Incorporated. Actionable Recommendations for Strategic Market Leadership

Industry leaders are encouraged to adopt a multifaceted approach to harness the full potential of the anti-rheumatics market. To remain competitive, it is essential to invest in robust R&D capabilities that focus on precision medicine and personalized therapies, ensuring that treatment options are tailored to individual patient needs. Expanding product portfolios across diverse drug classes and routes of administration can effectively address varying patient demographics and preferences. Leaders should also explore strategic partnerships and collaborations to accelerate innovation and expand market access, particularly in emerging economies where healthcare infrastructure is rapidly evolving. An emphasis on data-driven insights will enable decision-makers to identify untapped market segments and optimize distribution channels, including hospital, online, and retail pharmacies. Furthermore, leveraging digital technologies such as AI and machine learning can streamline clinical trials and enhance patient engagement. Regulatory compliance must remain at the forefront of any strategic initiative, with a proactive approach to meet evolving global standards. By embracing these recommendations, companies can not only mitigate market risks but also capitalize on emerging trends, ultimately driving sustainable growth and competitive differentiation in a constantly evolving healthcare landscape.

Conclusion: Synthesizing Insights for Future Growth

In summary, the anti-rheumatics market presents robust opportunities underpinned by transformative technological and regulatory advancements. The in-depth segmentation analysis, regional evaluations, and company performance insights collectively reinforce a narrative of dynamic growth and innovation. As the landscape continues to evolve with a focus on targeted therapies and patient-centric solutions, stakeholders are well-positioned to benefit from these changes by strategically aligning their business models with current market trends. This comprehensive summary encapsulates the critical areas that require focus and continued investment to ensure long-term success in the anti-rheumatics domain.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increase in the prevalence of rheumatic disorders
    • 5.1.1.2. Rise in awareness related to early screening and treatment of rheumatoid arthritis
    • 5.1.1.3. Growing emphasis on precision therapeutics and personalized medicine
  • 5.1.2. Restraints
    • 5.1.2.1. Side effects and safety issues associated with anti-rheumatic drugs
  • 5.1.3. Opportunities
    • 5.1.3.1. Government initiatives and support for the research and development of the rheumatic diseases
    • 5.1.3.2. Significant development and marketing of cost-effective biosimilars
  • 5.1.4. Challenges
    • 5.1.4.1. Complex drug development and approval processes
• 5.2. Market Segmentation Analysis
  • 5.2.1. Drug Class: Increasing adoption of nonsteroidal anti-inflammatory drugs due to their accessibility, affordability, and effective management of pain
  • 5.2.2. Route Of Administration: Advancements in oral drug formulations aiming to improve bioavailability and minimize adverse effects
  • 5.2.3. Type: Significant preference for prescription-based drugs in managing severe and chronic rheumatic diseases
  • 5.2.4. Disease Type: Evolving personalized medicine advancement in rheumatoid arthritis to optimize treatment outcomes and minimize side effects.
  • 5.2.5. Distribution Channel: Expanding online pharmacies for anti-rheumatic medication distribution
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Anti-Rheumatics Market, by Drug Class

• 6.1. Introduction
• 6.2. Corticosteroids
• 6.3. Disease Modifying Anti-rheumatics Drugs
  • 6.3.1. Biologic DMARDs
    • 6.3.1.1. B-cell Inhibitors
    • 6.3.1.2. Interleukin Inhibitors
    • 6.3.1.3. T-cell Co-stimulation Modulators
    • 6.3.1.4. Tumor Necrosis Factor (TNF) Inhibitors
  • 6.3.2. Conventional DMARDs
  • 6.3.3. Targeted Synthetic DMARDs
• 6.4. Nonsteroidal Anti-inflammatory Drugs
• 6.5. Uric Acid Drugs

7. Anti-Rheumatics Market, by Route Of Administration

• 7.1. Introduction
• 7.2. Injectable
• 7.3. Oral
• 7.4. Topical

8. Anti-Rheumatics Market, by Type

• 8.1. Introduction
• 8.2. Over-the-Counter Drugs
• 8.3. Prescription-Based Drugs

9. Anti-Rheumatics Market, by Disease Type

• 9.1. Introduction
• 9.2. Ankylosing Spondylitis
• 9.3. Bursitis
• 9.4. Gout
• 9.5. Juvenile Idiopathic Arthritis
• 9.6. Osteoarthritis
• 9.7. Osteoporosis
• 9.8. Polymyalgia Rheumatica
• 9.9. Psoriatic Arthritis
• 9.10. Rheumatoid Arthritis
• 9.11. Sjogren's Syndrome
• 9.12. Systemic Lupus Erythematosus
• 9.13. Systemic Sclerosis/Scleroderma
• 9.14. Tendinitis

10. Anti-Rheumatics Market, by Distribution Channel

• 10.1. Introduction
• 10.2. Hospital Pharmacies
• 10.3. Online Pharmacies
• 10.4. Retail Pharmacies

11. Americas Anti-Rheumatics Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Anti-Rheumatics Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Anti-Rheumatics Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
  • 14.3.1. Johnson & Johnson showcases advances in rheumatic disease treatments with 43 abstracts at ACR 2024
  • 14.3.2. FDA expands Shorla's JYLAMVO approval to combat pediatric oncology and autoimmune conditions
  • 14.3.3. DeepCure's DC-9476 methotrexate resistance in rheumatoid arthritis treatment
  • 14.3.4. FDA approval of Kevzara for treatment of pediatric and adult inflammatory arthritis
  • 14.3.5. Eisai and nippon medac launch Japan's first self-administered methotrexate pen
  • 14.3.6. Teva and Alvotech introduce SIMLANDI an interchangeable Humira biosimilar in the U.S.
  • 14.3.7. Kiniksa advances abiprubart in Phase 2b Trial for Sjogren's Disease, building on results from rheumatoid arthritis trial
  • 14.3.8. Fresenius Kabi's FDA approval of TYENNE tocilizumab biosimilar introduces in the anti-rheumatics market
  • 14.3.9. FDA approval revolutionizes rheumatic care with Novartis' Cosentyx
  • 14.3.10. Sandoz launches citrate-free high-concentration biosimilar Hyrimoz in the U.S. market
• 14.4. Strategy Analysis & Recommendation
  • 14.4.1. GlaxoSmithKline PLC
  • 14.4.2. Johnson & Johnson Services Inc.
  • 14.4.3. Novartis AG
  • 14.4.4. AbbVie Inc.

Companies Mentioned

• 1. AbbVie Inc.
• 2. Alvotech
• 3. Amgen Inc.
• 4. ANI Pharmaceuticals, Inc.
• 5. AstraZeneca PLC
• 6. Bayer AG
• 7. Biogen Inc.
• 8. Bristol-Myers Squibb Company
• 9. C. H. Boehringer Sohn AG & Co. KG
• 10. DeepCure
• 11. Eisai Co., Ltd.
• 12. Eli Lilly and Company
• 13. F. Hoffmann-La Roche Ltd.
• 14. Fresenius Kabi AG
• 15. Galapagos NV
• 16. Gilead Sciences, Inc.
• 17. GlaxoSmithKline PLC
• 18. ILTOO Pharma SAS
• 19. Johnson & Johnson Services Inc.
• 20. medac GmbH
• 21. Merck & Co., Inc.
• 22. Novartis AG
• 23. Otter Pharmaceuticals, LLC by Assertio Holdings, Inc.
• 24. Pfizer, Inc.
• 25. Regeneron Pharmaceuticals, Inc.
• 26. Sanofi SA
• 27. Takeda Pharmaceutical Company Limited
• 28. Teva Pharmaceutical Industries Ltd.
• 29. UCB S.A.
• 30. Vertex Pharmaceuticals Incorporated